Indirect comparison of the efficacy and safety of alirocumab and evolocumab on major cardiovascular events: a systematic review and network meta-analysis
BackgroundAlirocumab and evolocumab are proprotein convertase subtilisin/kexin type 9 inhibitors that significantly reduce the relative risk of cardiovascular events. However, the relative efficacy and safety of alirocumab and evolocumab in different patient groups still warrant further indirect com...
Sparad:
| Huvudupphov: | , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
Frontiers Media S.A.
2025-06-01
|
| Serie: | Frontiers in Pharmacology |
| Ämnen: | |
| Länkar: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1555508/full |
| Taggar: |
Inga taggar, Lägg till första taggen!
|